Credit (via Washington University in St. Louis/Shyam Kavuri, Ph. D.)
The top image shows untreated breast cancer cells with HER2 mutations. The bottom image shows how much these cells shrink after treatment with neratinib, an anti-HER2 drug currently in clinical trials.
The findings of new breast cancer research from Washington University could result in effective treatment for 4,000 additional patients in the United States each year. Scientists made the discovery after analyzing DNA sequencing data from 1,500 patients.
The research appears in the latest edition of Cancer Discovery.